However, a p-value of 0.126 (when comparing the <25% and >50% LDLR expression cohorts) certainly warrants re-examination in a larger cohort of high-grade glioma patients to refute a prognostic role more confidently for LDLR expression. The gene discussed is LDLR; the disease is glioma.